Paul G Abrams

US Patent:

RE38008, Feb 25, 2003

Filed:

Nov 29, 2001

Appl. No.:

09/995870

Inventors:

Paul G. Abrams - Seattle WA
Robert W. Schroff - Edmonds WA

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 39395

US Classification:

4241381, 4241781, 4241791, 4241801, 4241811, 4241411, 424 111

Abstract:

Methods for improved targeting of antibody, antibody fragments, peptides hormones, steroid hormones and conjugates thereof are disclosed. Enhanced delivery to target cells of antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for a population of cells of a mammal comprises steps of administering to said mammal an adequate dosage of blocking antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, and administering to said mammal an effective dosage of said antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for said population of cells. In the preferred embodiment, the specific antibodies are monoclonal antibodies directed toward tumor-associated antigen in man.

US Patent:

6767531, Jul 27, 2004

Filed:

Dec 11, 2001

Appl. No.:

10/014335

Inventors:

Alan R. Fritzberg - Olga WA
Paul G. Abrams - Seattle WA
Lauren Marie Tatalick - Redmond WA
Kent R. Thoelke - Seattle WA
James Kyle Bryan - Seattle WA
Mark D. Hylarides - Stanwood WA
Elizabeth K. John - San Diego WA

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 5100

US Classification:

424 165, 424 111, 534 15

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7070759, Jul 4, 2006

Filed:

Jan 24, 2005

Appl. No.:

11/041828

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 165, 424 91, 424 111, 534 15, 514836

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7097823, Aug 29, 2006

Filed:

Feb 23, 2004

Appl. No.:

10/784476

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

NEORX Corporation - Seattle WA

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 165, 424 111, 424 91, 534 15

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7408046, Aug 5, 2008

Filed:

Jun 30, 2004

Appl. No.:

10/882054

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

Poniard Pharmaceuticals, Inc. - Seattle WA

International Classification:

C07F 5/00

US Classification:

534 15, 424 111, 424 165, 424 91

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7696331, Apr 13, 2010

Filed:

Jun 19, 2008

Appl. No.:

12/142664

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

Poniard Pharmaceuticals, Inc. - Seattle WA

International Classification:

C07F 5/00

US Classification:

534 15, 424 111, 424 165, 424 91

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

20070053833, Mar 8, 2007

Filed:

Jul 12, 2006

Appl. No.:

11/485183

Inventors:

Alan Fritzberg - Olga WA, US
Paul Abrams - Seattle WA, US
Lauren Tatalick - Redmond WA, US
Kent Thoelke - Seattle WA, US
James Bryan - Seattle WA, US
Mark Hylarides - Stanwood WA, US
Elizabeth John - San Diego CA, US

International Classification:

A61K 51/00
A61K 31/66

US Classification:

424001110, 514109000, 600001000

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

51129540, May 12, 1992

Filed:

Apr 4, 1988

Appl. No.:

7/176851

Inventors:

Paul G. Abrams - Seattle WA
Ananthachari Srinivasan - Kirkland WA
Vivekananda M. Vrudhula - Mountlake Terrace WA

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

C07K 1702
A61K 3944

US Classification:

5303919

Abstract:

The activity of cytotoxic agents on target cells is enhanced through administration of a sensitizing agent to a patient prior to or simultaneously with administration of the cytotoxic agent. One or both of the two types of agents are attached to antibodies specific for the desired target cells, thereby enhancing the cytotoxic effect on target cells compared to non-target cells. The sensitizer and/or the cytotoxic agent may be attached to monoclonal antibodies specific for cancer cells to selectively eradicate the cancer cells while minimizing toxicity toward normal tissues.